Skip to main content
SpringerLink
Log in

Samarium 153Sm lexidronam: effective pain relief for bone metastases

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991 Mar; 9(3): 509–24

    PubMed  CAS  Google Scholar 

  2. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997 Jan; 69: 1–18

    Article  PubMed  CAS  Google Scholar 

  3. Goeckeler WF, Edwards B, Volkert WA, et al. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987; 28(4): 495–504

    PubMed  Google Scholar 

  4. Lewington VJ. Samarium 153Sm lexidronam: a viewpoint. Drugs Aging 1997 Nov; 11(5): 419

    Article  Google Scholar 

  5. Lamb HM, Faulds D. Samarium 153Sm lexidronam. Drugs Aging 1997 Nov; 11(5): 413–8

    Article  PubMed  CAS  Google Scholar 

  6. Silberstein EB. The treatment of painful osteoblastic metastases: what can we expect from nuclear oncology? J Nucl Med 1994 Dec; 35(12): 1994–5

    PubMed  CAS  Google Scholar 

  7. Singh A, Holmes RA, Farhangi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 1989; 30(11): 1814–8

    PubMed  CAS  Google Scholar 

  8. Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiation Oncology Biol Phys 1994; 30(5): 1187–94

    Article  CAS  Google Scholar 

  9. Porter AT, Ben-Josef E, Davis L. Systemic administration of new therapeutic radioisotopes, including phosphorous, strontium, samarium, and rhenium. Curr Opin Oncol 1994; 6: 607–10

    Article  PubMed  CAS  Google Scholar 

  10. Sartor O, Quick D, Reid R, et al. A double blind placebo controlled study of 153samarium-EDTMP for palliation of bone pain in patients with hormone-refractory prostate cancer [abstract no. 1252]. J Urol 1997 Apr; 157 Suppl.: 321

    Google Scholar 

  11. Serafini A, Quick D, Houston S, et al. Sm-153-EDTMP as palliative agent for patients with bone metastases [abstract no. 117]. J Nucl Med 1996 May; 37 Suppl.: 32P

    Google Scholar 

  12. Farhanghi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992 Aug; 33: 1451–8

    PubMed  CAS  Google Scholar 

  13. Turner JH, Ciaringbold PG, Hetherington EL, et al. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989 Dec; 7: 1926–31

    PubMed  CAS  Google Scholar 

  14. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993 Nov; 34: 1839–44

    PubMed  CAS  Google Scholar 

  15. Houston SJ, Ramirez A, Lazarus CR, et al. Experience with samarium-153-EDTMP for the treatment of patients with painful bone metastases [abstract no. P182]. Br J Cancer 1995 Apr; 71 Suppl. 24: 69

    Google Scholar 

  16. Resche I, Chatal J-F, Pecking A, et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33(10): 1583–91

    Article  PubMed  CAS  Google Scholar 

  17. Fossella FV, Kasi L, Holoye P, et al. Phase I/II study of multi-dose samarium-153-EDTMP for bone metastases [abstract no. 210]. Ann Oncol 1992 Nov; 3 Suppl. 5: 54

    Google Scholar 

  18. DuPont Merck Pharmaceutical Company. Quadramet™ (samarium Sm 153 lexidronam injection) prescribing information. North Billerica, USA, Feb 1997

    Google Scholar 

  19. Silberstein, EB. Samarium 153Sm lexidronam: a viewpoint. Drugs Aging 1997 Nov; 11(5): 419

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Samarium 153Sm lexidronam: effective pain relief for bone metastases. Drugs Ther. Perspect 12, 1–5 (1998). https://doi.org/10.2165/00042310-199812010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199812010-00001

Keywords

Search

Navigation